Phase 3 N=77 Drug Treatment for Pathologic Gambling Disorder
Gambling
Primary: Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS) — 16.9; 18.6; 9.7; 12.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 The Context of Gambling Treatment: Towards Creating an Online Service to Reduce Problem Gambling - Part Five
Problem Gambling
Primary: Changes in Gambling Frequency as Measured by Self Reported Frequency on 12 Different Types of Gambling. — -2 score on a scale
Phase 4 N=28 Acamprosate in the Treatment of Pathological Gambling
Pathological Gambling
Primary: The Primary Efficacy Measure Was the Yale-Brown Obsessive Compulsive Scale Modified for PG (YBOCS-PG). — -.985 units on a scale — p=0.05
Phase 2 N=43 Milk Thistle in Pathological Gambling
Pathological Gambling · Gambling Disorder
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — -11.76; -11.86 units on a scale
Phase 2 N=62 D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
Pathological Gambling
Primary: Subjective Reinforcement Self-report Scales — 4.8; 4.8; 9.5; 9.3 units on a scale
N/A N=26 The Effect of Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder
Gambling Addiction · Gambling Disorder · Gambling Disorder Treatment
Primary: Change in Self-Stigmatization Score as Measured by the Self-Stigma Scale (SSS). Baseline (Week 0) to Post-treatment (Week 4) and Follow-up (Week 8) — 82.77; 110.3…
Phase 2 N=28 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Gambling · Tobacco Use Disorder
Primary: Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score — 23.5; 20.4 units on a scale
Phase 2 N=34 Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
Pathological Gambling
Primary: Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling — 13.9 YBOCS score
Phase 2 N=29 Memantine Treatment Study of Pathological Gambling
Pathological Gambling
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — 21.8; 8.9 units on a scale
Phase 2 N=9 Investigation of Naltrexone for Pathological Gambling
Pathological Gambling
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (YBOCS-PG) — 16.0; 17.0; 10.0; 4.0 units on a scale
Phase 2 N=24 Tolcapone Treatment of Pathological Gambling
Pathological Gambling
Primary: Clinical Global Impression Scale (CGI) — 2.88 units on a scale
N/A N=80 Integrative Couple Treatment for Pathological Gambling
Pathological Gambling
Primary: Gambling Symptom Assessment Scale (G-SAS) — 18.52; 16.66; 6.85; 12.39 score on a scale
N/A N=19 Dopamine Responsivity in Gamblers
Pathological Gambling
Primary: Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale, Non-planning Subscale — -0.5 Correlation…
N/A N=60 A Psychotherapy Development Study for Internet Gaming
Internet Gaming Disorder
Primary: Percentage of Participants Who Completed All 6 Sessions — 40.6 percentage of participants
N/A N=36 Reducing Internet Gaming
Internet Gaming Disorder
Primary: Percentage of Participants Who Complete All 6 Sessions — 78.9 percentage of participants
N/A N=59 Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment
Pathological Gambling
Primary: Perceived Stress Scale — 15.2; 14.5 units on a scale
N/A N=245 QuitBet Phase II: A Digital Social Game That Pays You to Stop Smoking
Smoking Cessation
Primary: Number of Participants Who Reported no Cigarette Smoking During the Past 7 Days — 30; 35 Participants
Phase 2 N=10 Memantine Treatment of Compulsive Buying
Compulsive Buying
Primary: Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) — 22 units on a scale
N/A N=32 Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits
Drug Dependence · Alcohol Dependence
Primary: Hopkins Verbal Learning Test (HVLT) Total Recall — 17.27; 18.00; 15.27; 17.50 units on a scale
N/A N=161 An Addiction-Based Mobile Health Weight Loss Intervention With Coaching
Pediatric Obesity · Mobile Technology · Addiction
Primary: %BMIp95 — -1.9; -1.2; -1.5 percent
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
N/A N=91 A Virtual Arm to Stop Smoking
Cigarette Smoking
Primary: Self-report Measure of Abstinence in the Last 7 Days, Averaged Over Four Weeks, and Confirmed by Urine Samples. — 45; 46 participants
N/A N=53 Web-based Addiction Treatment: Cultural Adaptation With American Indians
Substance Use Disorders
Primary: Consecutive Weeks of Drug/Alcohol Abstinence — 2.0; 2.0 Weeks — p=0.437
N/A N=186 Preventing Addiction Related Suicide (PARS)
Suicide · Substance-Related Disorders
Primary: PARS Help-Seeking Scale — 0.57; 0.53 units on a scale
N/A N=412 Group Therapy for Nicotine Dependence: Mindfulness and Smoking
Smoking · Tobacco Use Cessation
Primary: Number of Participants With Smoking Abstinence — 21; 39; 43 Participants
Phase 2 N=20 Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction
Cocaine Addiction · Cocaine-related Disorder · Executive Dysfunction
Primary: Abstinence — 71.4; 16.6 percentage of participants
N/A N=30 Social Support Intervention for Addiction Recovery
Alcohol; Harmful Use · Alcohol
Primary: Recruitment Feasibility — 10 participants per month
N/A N=91 The Long-Term Treatment of Drug Addiction and Unemployment
Substance Abuse, Intravenous
Primary: The Percentage of Opiate- and Cocaine-negative Urine Samples — 44.9; 64.6 percentage of urine samples — p=.05
Phase 2 N=7 Double-Blind Naltrexone in Compulsive Sexual Behavior
Compulsive Sexual Behavior
Primary: Yale Brown Obsessive Compulsive Scale Modified for Compulsive Sexual Behavior (YBOCS) — 8; 9.33 units on a scale
Phase 2 N=18 The Effect of Glutamatergic Modulation on Cocaine Self-administration
Cocaine Dependence
Primary: Number of Choices to Self-administer Cocaine (Out of 5 Choices) — 1.61; 4.33 number of cocaine choices